CoChat

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

Fiskus, Warren, Cai, Tianyu, DiNardo, Courtney D., Kornblau, Steven M., Borthakur, Gautam, Kadia, Tapan M., Pemmaraju, Naveen, Bose, Prithviraj, Masarova, Lucia, Rajapakshe, Kimal, Perera, Dimuthu, Coarfa, Cristian, Mill, Christopher P., Saenz, Dyana T., Saenz, David N., Sun, Baohua, Khoury, Joseph D., Shen, Yu, Konopleva, Marina, Bhalla, Kapil N. · 2019 · Blood Cancer Journal
Cited by 62

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

First-generation bromodomain extra-terminal protein (BETP) inhibitors (BETi) (e.g., OTX015) that disrupt binding of BETP BRD4 to chromatin transcriptionally attenuate AML-relevant progrowth and prosurvival oncoproteins. BETi treatment induces apoptosis of AML BPCs, reduces in vivo AML burden and induces clinical remissions in a minority of AML patients. Clinical efficacy of more potent BETis, e.g., ABBV-075 (AbbVie, Inc.), is being evaluated. Venetoclax and A-1210477 bind and inhibit the antiapoptotic activity of BCL2 and MCL1, respectively, lowering the threshold for apoptosis. BETi treatment is shown here to perturb accessible chromatin and activity of enhancers/promoters, attenuating MYC, CDK6, MCL1 and BCL2, while inducing BIM, HEXIM1, CDKN1A expressions and apoptosis of AML cells. Treatment with venetoclax increased MCL1 protein levels, but cotreatment with ABBV-075 reduced MCL1 and Bcl-xL levels. ABBV-075 cotreatment synergistically induced apoptosis with venetoclax or A-1210477 in patient-derived, CD34+ AML cells. Compared to treatment with either agent alone, cotreatment with ABBV-075 and venetoclax was significantly more effective in reducing AML cell-burden and improving survival, without inducing toxicity, in AML-engrafted immune-depleted mice. These findings highlight the basis of superior activity and support interrogation of clinical efficacy and safety of cotreatment with BETi and BCL2 or MCL1 inhibitor in AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41408-018-0165-5

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 50

  1. Belkina, A. C. & Denis, G. V. BET domain co-regulators in obesity, inflammation and cancer. Nat. Rev. Cancer 12, 465–477 (2012). · DOI · Paper page
  2. Shi, J. & Vakoc, C. R. The mechanism behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 54, 728–736 (2014). · DOI · Paper page
  3. Itzen, F., Greifenberg, A. K., Bosken, C. A. & Geyer, M. Brd4 activates P-TEFB for RNA polymerase II CTD phosphorylation. Nucleic Acids Res. 42, 7577–7590 (2014). · DOI · Paper page
  4. Nechaev, S. & Adelman, K. Pol II waiting in the starting gates: regulating the transition from transcription initiation into productive elongation. Biochim. Biophys. Acta 1809, 34–45 (2011). · DOI · Paper page
  5. Bradner, J. E., Hnisz, D. & Young, R. A. Transcriptional addiction in cancer. Cell 168, 629–643 (2017). · DOI · Paper page
  6. Bhagwat, A. S., Lu, B. & Vakoc, C. R. Enhancer dysfunction in leukemia. Blood 131, 1795–1804 (2018). · DOI
  7. Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529–533 (2011). · DOI · Paper page
  8. Fiskus, W. et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol. Cancer Ther. 13, 1142–1154 (2014). · DOI · Paper page
  9. Dawson, M. A. et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia 28, 311–320 (2014). · DOI · Paper page
  10. Berthon, C. et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 3, e186–e195 (2016). · DOI · Paper page
  11. Braun, T. & Gardin, C. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML). Expert Opin. Investig. Drugs 26, 803–811 (2017). · DOI · Paper page
  12. Filippakapoulos, P. & Knapp, S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 13, 337–356 (2014). · DOI · Paper page
  13. McDaniel, K. F. et al. Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a potent and orally available bromodomain and extraterminal domain (BET) family bromodomain inhibitor. J. Med. Chem. 60, 8369–8384 (2017). · DOI · Paper page
  14. Tanaka, M. et al. Design and characterization of bivalent BET inhibitors. Nat. Chem. Biol. 12, 1089–1096 (2016). · DOI · Paper page
  15. Rhyasen, G. W. et al. AZD5153: a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies. Mol. Cancer Ther. 15, 2563–2574 (2016). · DOI · Paper page
  16. Hogg, S. J. et al. BET inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members. Mol. Cancer Ther. 15, 2030–2041 (2016). · DOI · Paper page
  17. Adams, J. M. & Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26, 1324–1337 (2007). · DOI · Paper page
  18. Dai, H., Meng, X. W. & Kaufmann, S. H. Mitochondrial apoptosis and BH3 mimetics. F1000Res. 5, 2804–2815 (2016). · DOI
  19. Leverson, J. D. et al. Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax. Cancer Discov. 7, 1376–1393 (2017). · DOI · Paper page
  20. Pan, R. et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 4, 362–375 (2014). · DOI · Paper page
  21. Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202–208 (2013). · DOI · Paper page
  22. Konopleva, M. et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 6, 1106–1117 (2016). · DOI · Paper page
  23. Tahir, S. K. et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. Bmc Cancer 17, 399 (2017). · DOI · Paper page
  24. Teh, T. C. et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia 32, 303–312 (2018). · DOI · Paper page
  25. Phillips, D. C. et al. Loss in MCL1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 5, e368 (2015). · DOI
  26. Bogenberger, J. M. et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 28, 1657–1665 (2014). · DOI · Paper page
  27. DiNardo, C. D. et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am. J. Hematol. 93, 401–407 (2018). · DOI · Paper page
  28. Soderquist, S., Eastman, R. & A. BCL2 inhibitors as anticancer drugs: a plethora of misleading BH3 mimetics. Mol. Cancer Ther. 15, 2011–2017 (2016). · DOI
  29. Valentin, R., Grabow, S. & Davids, M. S. The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood 132, 1248–1264 (2018). · DOI · Paper page
  30. Certo, M. et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9, 351–365 (2006). · DOI · Paper page
  31. Vo, T. T. et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151, 344–355 (2012). · DOI · Paper page
  32. Ni Chonghaile, T. et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334, 1129–1133 (2011). · DOI · Paper page
  33. Rooswinkel, R. W. et al. Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity. Blood 123, 2806–2815 (2014). · DOI · Paper page
  34. Dai, H. et al. Measurement of BH3-only protein tolerance. Cell Death Differ. 25, 282–293 (2018). · DOI
  35. Luedtke, D. A. et al. Inhibition of MCL1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduct. Target Ther. 2, 17012 (2017). · DOI
  36. Lin, K. H. et al. Targeting MCL1/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia. Sci. Rep. 6, 27696 (2016). · DOI · Paper page
  37. Saenz, D. T. et al. BET protein bromodomain inhibitor-based combinations are highly active against postmyeloproliferative neoplasm secondary AML cells. Leukemia 31, 678–687 (2017). · DOI
  38. Devaraj, S. G. et al. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Leukemia 30, 504–508 (2016). · DOI
  39. Bui, M. H. et al. preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies. Cancer Res. 77, 2976–2989 (2017). · DOI
  40. Lin, X. et al. HEXIM1 as a robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissues. Mol. Cancer Ther. 16, 388–396 (2017). · DOI
  41. Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311–322 (2016). · DOI · Paper page
  42. Fresquet, V., Rieger, M., Carolis, C., García-Barchino, M. J. & Martinez-Climent, J. A. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood 123, 4111–4119 (2014). · DOI · Paper page
  43. Rudin, C. M. et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163–3169 (2012). · DOI · Paper page
  44. Roberts, A. W. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30, 488–496 (2012). · DOI · Paper page
  45. Zhong, Q., Gao, W., Du, F. & Wang, X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of MCL1 and regulates apoptosis. Cell 121, 1085–1095 (2005). · DOI · Paper page
  46. Dey, J. et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci. Rep. 7, 18007 (2017). · DOI
  47. Ruefli-Brasse, A. & Reed, J. C. Therapeutics targeting Bcl-2 in hematological malignancies. Biochem. J. 474, 3643–3657 (2017). · DOI
  48. Kojima, K. et al. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle 5, 2778–2786 (2006). · DOI · Paper page
  49. Chan, S. M. et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 21, 178–184 (2015). · DOI · Paper page
  50. Lagadinou, E. D. et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329–341 (2013). · DOI · Paper page

Cited by

See all 62

Metadata

Authors
Fiskus, W., Cai, T., DiNardo, C. D., Kornblau, S. M., Borthakur, G., Kadia, T. M., Pemmaraju, N., Bose, P., Masarova, L., Rajapakshe, K., Perera, D., Coarfa, C., Mill, C. P., Saenz, D. T., Saenz, D. N., Sun, B., Khoury, J. D., Shen, Y., Konopleva, M., & Bhalla, K. N.
Venue
Blood Cancer Journal
Published
2019-01-15
Volume
9
Issue
2
ISSN
2044-5385
Cited by
62
References
10
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. https://app.cochat.ai/papers/10.1038/s41408-018-0165-5
The paper
Fiskus, W., Cai, T., DiNardo, C. D., Kornblau, S. M., Borthakur, G., Kadia, T. M., Pemmaraju, N., Bose, P., Masarova, L., Rajapakshe, K., Perera, D., Coarfa, C., Mill, C. P., Saenz, D. T., Saenz, D. N., Sun, B., Khoury, J. D., Shen, Y., Konopleva, M., & Bhalla, K. N. (2019). Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer Journal. https://doi.org/10.1038/s41408-018-0165-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.